Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds

• Status: Not yet recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the safety and efficacy of low-dose (50mg) aspirin as a secondary prevention drug in patients with Non-Cardioembolic Ischemic Stroke accompanied by cerebral microbleeds.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xijing Hospital
• Collaborators: Baoji Central Hospital; Shaanxi Provincial People's Hospital; Tang-Du Hospital; The First Affiliated Hospital of Jiaotong University; The First Affiliated Hospital of Xi'an Medical University; Xi'an Central Hospital; Xiangyang Central Hospital; Xianyang Central Hospital
• Treatments: Aspirin

Criteria

Inclusion Criteria:

1. Patients with cerebral infarction diagnosed clinically as non-cardioembolic ischemic stroke;

2. Age ≥ 18 years;

3. Onset time ≤ 3 weeks;

4. At least one cerebral microbleeds lesion was found on SWI;

5. Informed consent was signed.

Exclusion Criteria:

1. Patients with symptomatic intracranial hemorrhage;

2. No microbleeds or bleeding lesion > 10 mm was found on SWI;

3. Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present;

4. Clear anticoagulant indications (such as atrial fibrillation);

5. There are contraindications for aspirin use;

6. The focus of microbleeds is limited to the cortex or other evidence suggests that the patient has cerebral amyloid angiopathy;

7. Patients with coronary heart disease or other diseases need to take antiplatelet drugs;

8. Serious systemic diseases;

9. Refusal to sign informed consent or poor compliance.